Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany

Journal of Clinical Microbiology

Volumn 53, Issue 8, 2015, Pages 2509-2516

  Iftner, Thomas ^a   Becker, Sven ^a   Neis, Klaus Joachim ^b   Castanon, Alejandra ^c   Iftner, Angelika ^a   Holz, Arbara ^a   Staebler, Annette ^a   Henes, Melanie ^a   Rall, Katharina ^a   Haedicke, Juliane ^a   Von Weyhern, Claus Hann ^a   Clad, Andreas ^d   Brucker, Sara ^a   Sasieni, Peter ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ETC European Training Center for Gynecologic Endoscopy and Gynecologic Surgery   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; GERMANY; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS RNA TEST; HUMAN PAPILLOMAVIRUS TYPE 67; HUMAN TISSUE; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSTICS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPARATIVE STUDY; CYTOCHEMISTRY; CYTOLOGY; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; GENETICS; MIDDLE AGED; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROCEDURES;

HUMAN PAPILLOMAVIRUS;

MESSENGER RNA; VIRUS DNA; VIRUS RNA;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; GERMANY; HISTOCYTOCHEMISTRY; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 84938118569     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01013-15     Document Type: Article

References (36)

1. Schenck U, von Karsa L. 2000. Cervical cancer screening in Germany. Eur J Cancer 36:2221-2226. http://dx.doi.org/10.1016/S0959-8049(00)00313-0.
2. Robert Koch-Institut. 2013. Krebs in Deutschland 2009/2010. Robert Koch-Institut, Berlin, Germany.
3. Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Voigt K, Gibis B, Holzel D, Goldie SJ. 2006. The German cervical cancer screening model: development and validation of a decisionanalytic model for cervical cancer screening in Germany. Eur J Public Health 16:185-192. http://dx.doi.org/10.1093/eurpub/cki163.
4. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5):F88-F99. http://dx.doi.org/10.1016/j.vaccine.2012.06.095.
5. Dillner J. 2013. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 25:11-16. http://dx.doi.org/10.1097/GCO.0b013e32835c5d10.
6. Castle PE, de Sanjose S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. 2012. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 30(Suppl 5):F117-F122. http://dx.doi.org/10.1016/j.vaccine.2012.05.071.
7. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 137:516-542. http://dx.doi.org/10.1309/AJCPTGD94EVRSJCG.
8. Iftner T, Villa LL. 2003. Chapter 12: human papillomavirus technologies. J Natl Cancer Inst Monogr 2003:80-88. http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003487.
9. Arbyn M, Tommasino M, Depuydt C, Dillner J. 2014. Are 20 human papillomavirus types causing cervical cancer? J Pathol 234:431-435. http://dx.doi.org/10.1002/path.4424.
10. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N. 2011. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology. J Clin Microbiol 49:1071-1076. http://dx.doi.org/10.1128/JCM.01674-10.
11. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. 2009. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 45(Suppl 1): S55-S61. http://dx.doi.org/10.1016/S1386-6532(09)70009-5.
12. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, Ruiz F, Smith JS. 2011. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 129:691-701. http://dx.doi.org/10.1002/ijc.25726.
13. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Smith JS. 2012. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Gynecol Oncol 125:175-180. http://dx.doi.org/10.1016/j.ygyno.2012.01.002.
14. Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Perez AG, Chavez-Aviles MN, Belinson J. 2013. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer 23:513-518. http://dx.doi.org/10.1097/IGC.0b013e318280f3bc.
15. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A. 2011. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 49:557-564. http://dx.doi.org/10.1128/JCM.02147-10.
16. Reuschenbach M, Clad A, von Knebel Doeberitz C, Wentzensen N, Rahmsdorf J, Schaffrath F, Griesser H, Freudenberg N, von Knebel Doeberitz M. 2010. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol 119:98-105. http://dx.doi.org/10.1016/j.ygyno.2010.06.011.
17. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17:3033-3042. http://dx.doi.org/10.1158/1055-9965.EPI-08-0508.
18. Wu R, Belinson SE, Du H, Na W, Qu X, Wu R, Liu Y, Wang C, Zhou Y, Zhang L, Belinson JL. 2010. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. Int J Gynecol Cancer 20:1411-1414. http://dx.doi.org/10.1111/IGC.0b013e3181f29547.
19. Petry KU, Menton S, Menton M, van Loenen-Frosch F, Gomes HD, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. 2003. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88:1570-1577. http://dx.doi.org/10.1038/sj.bjc.6600918.
20. Boehmer G, Wang L, Iftner A, Holz B, Haedicke J, von Wasielewski R, Martus P, Iftner T. 2014. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.BMCInfect Dis 14:674. http://dx.doi.org/10.1186/s12879-014-0674-1.
21. Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Schulze-Rath R, Iftner T. 2012. Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84: results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 12:367. http://dx.doi.org/10.1186/1471-2334-12-367.
22. Grimm M, Iftner T, Altaki H, Iftner A, Peters JP, Munz A, Reinert S. 2014. Detection of mutation-specific epidermal growth factor receptor (E746-A750del) and lack of detection of human papillomavirus in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 43:1199-1205. http://dx.doi.org/10.1016/j.ijom.2014.04.006.
23. Fuessel Haws AL, He Q, Rady PL, Zhang L, Grady J, Hughes TK, Stisser K, Konig R, Tyring SK. 2004. Nested PCR with the PGMY09/11 and GP5/6 primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 122:87-93. http://dx.doi.org/10.1016/j.jviromet.2004.08.007.
24. Sasieni P. 2001. Estimating prevalence when the true disease status is incompletely ascertained. Stat Med 20:935-949. http://dx.doi.org/10.1002/sim.907.
25. Bonett DG, Price RM. 2012. Adjusted Wald confidence interval for a difference of binomial proportions based on paired data. J Educ Behav Stat 37:479-488. http://dx.doi.org/10.3102/1076998611411915.
26. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. 2007. Prevalence of HPV infection among females in the United States. JAMA 297:813-819. http://dx.doi.org/10.1001/jama.297.8.813.
27. Halec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimera N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M. 2014. Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol 234:441-451. http://dx.doi.org/10.1002/path.4405.
28. Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. 2013. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 445:224-231. http://dx.doi.org/10.1016/j.virol.2013.07.015.
29. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. 2008. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol 46:2595-2604. http://dx.doi.org/10.1128/JCM.00824-08.
30. Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, Moscicki AB. 2013. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis 207:1286-1294. http://dx.doi.org/10.1093/infdis/jit018.
31. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357:1589-1597. http://dx.doi.org/10.1056/NEJMoa073204.
32. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772. http://dx.doi.org/10.1016/S0140-6736(07)61450-0.
33. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516-520. http://dx.doi.org/10.1002/ijc.24010.
34. Kjaer SK, Frederiksen K, Munk C, Iftner T. 2010. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102:1478-1488. http://dx.doi.org/10.1093/jnci/djq356.
35. Wright TC, Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+cytology-negative results. Am J Clin Pathol 136:578-586. http://dx.doi.org/10.1309/AJCPTUS5EXAS6DKZ.
36. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specificHPVtesting in clinical practice. J Natl Cancer Inst 97:1072-1079. http://dx.doi.org/10.1093/jnci/dji187.